Remove tag access-medicines
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). The challenge of providing adequate access to the peripheral EU markets is quite evident. Europe’s forgotten territories.

Drugs 147
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Access to oncology medicines varies across countries, and their cost against safety/efficacy is generally perceived as being low, such as in the US. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds August 19, 2022: Inclusion and Diversity in Clinical Trials: Actionable Steps to Drive Lasting Change (Gerald Bloomfield, MD, MPH; Michelle Kelsey, MD)

Rethinking Clinical Trials

Associate Professor with Tenure, Medicine. Duke University School of Medicine. Assistant Professor of Medicine. Duke University School of Medicine. ? ? ? ? ? ? ? ? ? ?. Speakers. Gerald Bloomfield, MD, MPH. Associate Professor, Global Health. Michelle Kelsey, MD. Diversity, Inclusion. Key Points. Learn more.

article thumbnail

Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin

Roots Analysis

It is worth noting that smart labels contain a transponder code which can be read by sophisticated devices, including radio frequency identification device (RFID) tags and near-field communication (NFC) chips. While most smartphones can read NFC chips, RFID tags can only be read by specialized receivers.

article thumbnail

Grand Rounds Ethics and Regulatory Series November 11, 2022: Data Sharing and Pragmatic Clinical Trials: Law & Ethics Amidst a Changing Policy Landscape (Stephanie Morain, PhD, MPH; Kayte Spector-Bagdady, JD, MBioethics)

Rethinking Clinical Trials

Associate Director, Center for Bioethics & Social Sciences in Medicine. The government has made an interesting transition to focusing on sharing data that are generated in research for secondary analyses but then shifted to wanting access to data from the primary analysis. Kayte Spector-Bagdady, JD, MBioethics. Key Points.

article thumbnail

Grand Rounds May 5, 2023: All of Us Research Program: Improving Health Through Diverse Technology, Huge Cohorts, and Precision Medicine (Joshua C. Denny, MD, MS)

Rethinking Clinical Trials

Denny, MD, MS CEO, All of Us Research Program Slides Keywords Precision Medicine, All of Us Research Program Key Points The mission of the All of Us Research Program is to accelerate health research and medical breakthroughs, enabling individualized prevention, treatment, and care for all of us. It is currently open to U.S.

Medicine 130
article thumbnail

Grand Rounds October 28, 2022: The HERO (Healthcare Worker Exposure Response & Outcomes) Program: An Online Community to Support Observational Studies, Randomized Trials, and Long-Term Safety Surveillance (Emily O’Brien, PhD, FAHA; Russell Rothman, MD, MPP)

Rethinking Clinical Trials

Duke University School of Medicine. Director, Vanderbilt Institute for Medicine and Public Health. Important issues early on included COVID-19’s effects on the workplace, vaccine access and willingness, and impact on home life. Emily O’Brien, PhD, FAHA. Associate Professor. Duke Clinical Research Institute.

Trials 130